The Q3 results were below our estimates and market expectations. Each segment continues to tussle with its respective problems and adopt mitigating strategies. We expect Household segment to end its year in positive territory. Our optimism on the Bioenergy segment is fuelled by recent events in the US, China and Brazil. We understand that new product launches are still in the nascent stages. Thus, we opt for a watchful approach. Estimates are revised upwards. No change in stock recommendation
25 Oct 2018
Q3 performance below estimates
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q3 performance below estimates
Novonesis A/S (Novozymes A/S) Class B (NZYM:WBO) | 0 0 2.6% | Mkt Cap: 80,754m
- Published:
25 Oct 2018 -
Author:
Ankush Kathuria -
Pages:
3
The Q3 results were below our estimates and market expectations. Each segment continues to tussle with its respective problems and adopt mitigating strategies. We expect Household segment to end its year in positive territory. Our optimism on the Bioenergy segment is fuelled by recent events in the US, China and Brazil. We understand that new product launches are still in the nascent stages. Thus, we opt for a watchful approach. Estimates are revised upwards. No change in stock recommendation